University of California

Other

Daniel L Kaufman

Mark G Erlander

Allan J Tobin

Jide Tian

Robert H Edwards

Christopher J Evans

Duane E Keith, Jr

Michael J Clare-Salzler

Ofer Spottheim

Lorraine Hanssen

Dan Zekzer

Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).

Enhancing GABA's ability to modulate immune responses

In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

In accordance with the present invention, an interactive user display application is provided. The application displays and refreshes images that are intended to represent users or members of a social network or other web-based service. Using these images, the interactive user display application allows a user of the application to interact with other users or their profiles while viewing their images or while interacting with or consuming media.

Systems and methods for interactively displaying user images

Isolated polypeptides useful in ameliorating GAD-associated autoimmune disease as well as diagnostic and therapeutic methods of using the peptides are disclosed.

Cloned glutamic acid decarboxylase

A securing device for securing a wall to an I-beam. The securing device includes two members that coupled to the sides of an I-beam and are secured together so as to couple the securing device to the I-beam. The two members define a surface that is spaced from the bottom surface of the I-beam that can receive fasteners and the thickness of the two member is such that ordinary fasteners can be used to secure a wall component to the two members of the securing device thereby reducing the need to drill, weld or otherwise attach wall members directly to the I-beam.

Clamping device for securing metal struts to I-beams for interior wall construction

An adhesive skin protector that filters sunlight harmful to skin lesions. The protector includes at least one adhesive layer adapted to adhere to an area of skin having a skin lesion; and at least one filter layer attached to said adhesive layer, the at least one filter layer being adapted to filter sunlight harmful to the skin lesion.

Skin lesion protector

Recombinant forms of isolated and purified delta opioid receptors and methods to screen for compounds interactive with delta opioid receptors are described.

DNA molecules encoding opioid receptors and methods of use thereof

The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably, the methods and compositions utilize agents which interfere with the ability of the major histocompatibility complex (MHC) Class I molecule (MHC I) to inhibit neurite outgrowth. Such agents include antibodies directed to MHC I, MHC I fragments and/or analogs, and agents which interfere with MHC I interaction with its neuronal receptor and the receptor's signaling pathway.

Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule

The invention provides cDNA molecules comprising a part of the cDNA sequence of GADwhich encode at least one epitope for autoantibodies to GAD. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD. In another embodiment, the invention provides for the detection of autoantibodies to GADusing the GADpolypeptides coded for by the cDNA molecules of the invention.

Nucleic acid encoding GAD65

Genes encoding opioid receptors (including opioid-like receptor (ORL) proteins) can be retrieved from vertebrate libraries using the murine probe disclosed herein under low-stringency conditions. The DNA sequence shown inor its complement can be used to obtain the human delta, kappa and mu genes as well as the murine mu gene and human ORL-1. The probe provided encodes the murine delta opioid receptor.

Opioid receptors and methods of use

cDNA molecules coding for GAD polypeptide are disclosed. The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD which encode at least one epitope for autoantibodies to GAD . The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD . The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD . In another embodiment, the invention provides for the detection of autoantibodies to GAD using the GAD polypeptides coded for by the cDNA molecules of the invention.

Growing community of inventors

Santa Monica, CA, United States of America

Daniel L Kaufman